BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 32948129)

  • 1. Survival outcomes in men with a positive family history of prostate cancer: a registry based study.
    Ang M; Borg M; O'Callaghan ME;
    BMC Cancer; 2020 Sep; 20(1):894. PubMed ID: 32948129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Men presenting with prostate-specific antigen (PSA) values of over 100 ng/mL.
    Ang M; Rajcic B; Foreman D; Moretti K; O'Callaghan ME
    BJU Int; 2016 Apr; 117 Suppl 4():68-75. PubMed ID: 26890320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radical prostatectomy in Denmark: Survival analysis and temporal trends in clinicopathological parameters with up to 20 years of follow-up.
    Heering M; Berg KD; Brasso K; Iversen P; Røder MA
    Surg Oncol; 2017 Mar; 26(1):21-27. PubMed ID: 28317581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer outcomes for men who present with symptoms at diagnosis.
    Beckmann KR; O'Callaghan ME; Ruseckaite R; Kinnear N; Miller C; Evans S; Roder DM; Moretti K;
    BJU Int; 2017 Jun; 119(6):862-871. PubMed ID: 27489140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No Detrimental Effect of a Positive Family History on Long-Term Outcomes Following Radical Prostatectomy.
    Brath JM; Grill S; Ankerst DP; Thompson IM; Gschwend JE; Herkommer K
    J Urol; 2016 Feb; 195(2):343-8. PubMed ID: 26239337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Familial prostate cancer: a different disease?
    Kupelian PA; Klein EA; Witte JS; Kupelian VA; Suh JH
    J Urol; 1997 Dec; 158(6):2197-201. PubMed ID: 9366343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Active Surveillance Versus Radical Prostatectomy in Favorable-risk Localized Prostate Cancer.
    Thomsen FB; Røder MA; Jakobsen H; Langkilde NC; Borre M; Jakobsen EB; Frey A; Lund L; Lunden D; Dahl C; Brasso K
    Clin Genitourin Cancer; 2019 Aug; 17(4):e814-e821. PubMed ID: 31196798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of very high-risk prostate cancer after radical prostatectomy: Validation study from 3 centers.
    Sundi D; Tosoian JJ; Nyame YA; Alam R; Achim M; Reichard CA; Li J; Wilkins L; Schwen Z; Han M; Davis JW; Klein EA; Schaeffer EM; Stephenson AJ; Ross AE; Chapin BF
    Cancer; 2019 Feb; 125(3):391-397. PubMed ID: 30423193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer survival among statin users after prostatectomy in a Finnish nationwide cohort.
    Joentausta RM; Rannikko A; Murtola TJ
    Prostate; 2019 May; 79(6):583-591. PubMed ID: 30652328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Family History of Lethal Prostate Cancer and Risk of Aggressive Prostate Cancer in Patients Undergoing Radical Prostatectomy.
    Raheem OA; Cohen SA; Parsons JK; Palazzi KL; Kane CJ
    Sci Rep; 2015 Jun; 5():10544. PubMed ID: 26112134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary Gleason grade 4 at the positive margin is associated with metastasis and death among patients with Gleason 7 prostate cancer undergoing radical prostatectomy.
    Viers BR; Sukov WR; Gettman MT; Rangel LJ; Bergstralh EJ; Frank I; Tollefson MK; Thompson RH; Boorjian SA; Karnes RJ
    Eur Urol; 2014 Dec; 66(6):1116-24. PubMed ID: 25052213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term radical prostatectomy outcomes among participants from the European Randomized Study of Screening for Prostate Cancer (ERSPC) Rotterdam.
    Loeb S; Zhu X; Schroder FH; Roobol MJ
    BJU Int; 2012 Dec; 110(11):1678-83. PubMed ID: 22998182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved decision making in intermediate-risk prostate cancer: a multicenter study on pathologic and oncologic outcomes after radical prostatectomy.
    Beauval JB; Ploussard G; Cabarrou B; Roumiguié M; Ouzzane A; Gas J; Goujon A; Marcq G; Mathieu R; Vincendeau S; Cathelineau X; Mongiat-Artus P; Salomon L; Soulié M; Méjean A; de La Taille A; Rouprêt M; Rozet F;
    World J Urol; 2017 Aug; 35(8):1191-1197. PubMed ID: 27987030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between use of β-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease.
    Grytli HH; Fagerland MW; Fosså SD; Taskén KA
    Eur Urol; 2014 Mar; 65(3):635-41. PubMed ID: 23351721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer.
    Ham WS; Chalfin HJ; Feng Z; Trock BJ; Epstein JI; Cheung C; Humphreys E; Partin AW; Han M
    Eur Urol; 2017 Jun; 71(6):907-912. PubMed ID: 27876305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Localised prostate cancer in elderly men aged 80-89 years, findings from a population-based registry.
    Vatandoust S; Kichenadasse G; O'Callaghan M; Vincent AD; Kopsaftis T; Walsh S; Borg M; Karapetis CS; Moretti K
    BJU Int; 2018 May; 121 Suppl 3():48-54. PubMed ID: 29603585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
    Van Den Eeden SK; Lu R; Zhang N; Quesenberry CP; Shan J; Han JS; Tsiatis AC; Leimpeter AD; Lawrence HJ; Febbo PG; Presti JC
    Eur Urol; 2018 Jan; 73(1):129-138. PubMed ID: 28988753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of β-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy.
    Grytli HH; Fagerland MW; Fosså SD; Taskén KA; Håheim LL
    Prostate; 2013 Feb; 73(3):250-60. PubMed ID: 22821802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stage at presentation and survival outcomes of patients with Gleason 8-10 prostate cancer and low prostate-specific antigen.
    Falchook AD; Martin NE; Basak R; Smith AB; Milowsky MI; Chen RC
    Urol Oncol; 2016 Mar; 34(3):119.e19-26. PubMed ID: 26526383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.